What Are Cancer Biomarkers?
A Plain-English Guide
A biomarker is a measurable signal in your blood or tissue that tells your doctor what type of cancer you have and which treatments are most likely to work for your tumor.
Biomarker testing moves your care from one-size-fits-all to a treatment plan built around you — here’s what you need to know.
Reviewed by XpertPatient Medical Advisory · Updated · Sources: NCI · ACS · ASCO · NIH/PMC
What Is a Cancer Biomarker?
A cancer biomarker is a protein, gene, or molecule your cancer produces — or that your body produces in response to cancer — that doctors can measure to learn specific things about your tumor.
Think of a biomarker as a clue your cancer leaves behind. It can be a protein, a gene, or a small molecule found in your blood, tissue, or other body fluids. Doctors use these clues to learn specific things about your cancer.
Not all cancers of the same type are the same. Two people with breast cancer, for example, can have very different cancers based on their biomarkers. That’s why biomarker testing is such a big deal — it helps your care team choose the treatment that fits your specific cancer, not just any breast cancer.
This is called precision medicine— matching treatment to the unique biology of your tumor. Biomarker testing is how that matching happens.
What Can a Biomarker Tell Your Doctor?
Biomarkers do four jobs: they diagnose the cancer, predict how it may behave, predict which treatment will work, and monitor whether treatment is working.
🔍 Diagnostic Biomarker
Answers: “What type of cancer is this?”
Helps confirm that you have cancer and identifies what type or subtype it is. Like a label on the cancer that tells doctors what they’re dealing with.
Example: AFP for liver cancer
📊 Prognostic Biomarker
Answers: “How might my cancer behave over time?”
Tells your doctor how the cancer is likely to behave over time — whether it may grow slowly or quickly, and the chance it might come back. This helps with planning.
Example: Ki-67 in breast cancer
🎯 Predictive Biomarker
Answers: “Will this specific treatment work for my cancer?”
This is the most powerful type. It predicts whether a specific treatment — like a targeted drug or immunotherapy — will work for your cancer. It’s like a key that unlocks the right treatment.
Example: HER2 for trastuzumab
📈 Monitoring Biomarker
Answers: “Is my treatment working?”
Tracks how well your treatment is working. If a biomarker level drops, it’s often a sign the treatment is helping. If it rises, your doctor may want to adjust your plan.
Example: PSA during prostate treatment
How Are Biomarkers Found?
Biomarkers are found through a tissue biopsy, a blood test, gene sequencing, liquid biopsy, FISH, or flow cytometry — your doctor picks the test based on your cancer type and the biomarker.
Tissue Test (Biopsy)
A small sample of your tumor is removed and checked under a microscope or tested in a lab. This is the most common way biomarkers are found.
Blood Test
Some biomarkers, like PSA or AFP, are found right in your blood. Easy to do — no biopsy needed.
Gene Sequencing (NGS)
Next-generation sequencing reads the DNA in your cancer cells to find mutations like EGFR or BRCA. Very detailed and covers many genes at once.
Liquid Biopsy
Finds pieces of cancer DNA floating in your bloodstream. Useful when a tissue biopsy is hard to do, or to track cancer over time.
FISH Test
Looks for specific gene changes using fluorescent “tags” that light up under a special microscope. Often used to confirm HER2 or ALK status.
Flow Cytometry
Measures proteins on the surface of cells in a blood sample. Commonly used in blood cancers like leukemia and lymphoma.
Biomarkers by Cancer Type
Breast Cancer Biomarkers
The most important breast cancer biomarkers are ER, PR, and HER2 — together they determine whether hormone therapy or targeted drugs like Herceptin are likely to work for your tumor.
Prostate Cancer Biomarkers
PSA (Prostate-Specific Antigen) is the primary biomarker for prostate cancer — used for screening, diagnosis, and monitoring — while newer markers like PCA3 help reduce unnecessary biopsies.
Lung Cancer Biomarkers
All newly diagnosed non-small cell lung cancer patients should have comprehensive biomarker testing — EGFR, ALK, KRAS, and PD-L1 together determine whether targeted therapy or immunotherapy is the right approach.
Bladder Cancer Biomarkers
FGFR3 mutation testing is the most important new biomarker in bladder cancer — if your tumor carries this mutation, the targeted drug erdafitinib may be an FDA-approved option.
Colon Cancer Biomarkers
RAS mutation status (KRAS/NRAS) and mismatch repair testing (MSI-H/dMMR) must be completed before any treatment begins — they directly determine which drugs can and cannot help.
Endometrial Cancer Biomarkers
Molecular classification now places endometrial cancers into four groups — POLE-mutated, MSI-H/dMMR, p53-abnormal, and no specific molecular profile — and each group calls for a different treatment approach.
Kidney (Renal) Cancer Biomarkers
VHL gene loss drives most clear cell kidney cancers by triggering a blood vessel growth signal — VEGF-targeting drugs like sunitinib and pazopanib are designed specifically to block it.
Leukemia Biomarkers
BCR-ABL1 — the Philadelphia chromosome — defines CML and was the first major precision oncology target: imatinib (Gleevec) transformed CML from a fatal disease into a manageable condition.
Liver Cancer Biomarkers
Alpha-fetoprotein (AFP) is the primary blood marker for liver cancer — a simple blood draw that helps confirm diagnosis and track whether treatment is working.
Melanoma Biomarkers
BRAF V600E — present in roughly half of all melanomas — is one of the most actionable mutations in oncology: BRAF+MEK inhibitor combinations can produce rapid, significant tumor shrinkage.
Multiple Myeloma Biomarkers
M protein — the abnormal antibody secreted by myeloma cells — is the central biomarker of multiple myeloma: its level in blood or urine directly measures disease activity and whether treatment is working.
Non-Hodgkin Lymphoma Biomarkers
CD20 status is the first biomarker checked in most B-cell lymphomas — CD20-positive tumors respond to rituximab, one of the most successful targeted cancer therapies in medical history.
Pancreatic Cancer Biomarkers
BRCA1/BRCA2 testing is critical for all pancreatic cancer patients — if you carry an inherited BRCA mutation, the PARP inhibitor olaparib is FDA-approved as maintenance therapy for metastatic disease after first-line chemotherapy.
Rectal Cancer Biomarkers
MSI-H/dMMR rectal cancer is producing some of the most remarkable results in oncology — recent trials show immunotherapy alone achieving complete responses in some patients, potentially avoiding surgery.
Biomarker FAQs
What is a cancer biomarker?
A cancer biomarker is a measurable signal— such as a protein, gene mutation, or molecule — found in blood, tissue, or body fluids. It tells doctors what type of cancer you have, how it may grow, and which treatments are most likely to work. Biomarker testing is the foundation of precision medicine.
What is the difference between a predictive and a prognostic biomarker?
A predictive biomarker tells whether a specific treatment will work for your cancer— HER2 predicts trastuzumab response. A prognostic biomarker tells how the cancer may behave over time, independent of treatment — Ki-67 in breast cancer is an example.
What biomarkers are tested for breast cancer?
Key breast cancer biomarkers are ER, PR, HER2, Ki-67, and BRCA1/BRCA2.ER and PR determine whether hormone therapy works. HER2-positive status opens access to trastuzumab (Herceptin). BRCA mutations affect hereditary risk and PARP inhibitor eligibility. See the breast cancer biomarkers deep dive.
What biomarkers are tested for lung cancer?
The main lung cancer biomarkers are EGFR, ALK, KRAS, PD-L1, and TP53.Every newly diagnosed non-small cell lung cancer patient should have comprehensive biomarker testing. EGFR and ALK determine targeted therapy eligibility. PD-L1 guides immunotherapy decisions. See the lung cancer biomarkers deep dive.
Will my insurance pay for biomarker testing?
Yes, in most cases.Most major insurance plans and Medicare cover biomarker tests when your doctor orders them as part of your cancer care. Coverage has expanded a lot in recent years. Always double-check with your insurance before testing — ask your care team’s billing office for help.
What if my biomarker test comes back negative or unclear?
A negative result doesn’t mean you’ re out of options.It means that one treatment target isn’t present — other options remain. An unclear result may mean your doctor wants to retest or try a different method. Always talk through your results with your oncologist.
Can cancer biomarkers change over time?
Yes — cancer cells can evolve, especially after treatment.Your doctor may repeat testing if your cancer comes back or stops responding. Liquid biopsy makes repeat testing easier — it’s just a blood draw.
Should I ask about comprehensive genomic profiling (CGP)?
Yes — CGP tests hundreds of biomarkers at onceand can find treatment options single-marker tests would miss. It’s most often recommended for advanced or hard-to-treat cancers. Ask your oncologist if it’ s right for your situation.
What questions should I ask my doctor about biomarker testing?
Start with these four:“Has my tumor been tested for biomarkers?” / “Which biomarkers are most important for my cancer type?” / “Are there targeted therapies or clinical trials based on my results?” / “Should I have comprehensive genomic profiling?”
